|
gptkbp:instance_of
|
gptkb:biotechnology
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
Biogen's manufacturing facility in 2019
|
|
gptkbp:awards
|
gptkb:Best_CMO_Award_2020
gptkb:Global_Bioprocessing_Excellence_Award_2021
|
|
gptkbp:ceo
|
John Rim
|
|
gptkbp:certification
|
FDA approved
EMA approved
KFDA approved
|
|
gptkbp:collaboration
|
gptkb:Harvard_University
gptkb:University_of_California,_San_Diego
gptkb:MIT
|
|
gptkbp:community_engagement
|
healthcare initiatives
environmental conservation efforts
local education programs
|
|
gptkbp:expansion
|
new plant in Songdo
|
|
gptkbp:focus
|
monoclonal antibodies
biosimilars
cell and gene therapies
|
|
gptkbp:founded
|
gptkb:2011
|
|
gptkbp:headquarters
|
gptkb:Incheon,_South_Korea
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Samsung Biologics
|
|
gptkbp:investment
|
R& D
|
|
gptkbp:market_position
|
gptkb:Europe
gptkb:Asia
gptkb:North_America
global
|
|
gptkbp:number_of_employees
|
over 2,000
|
|
gptkbp:parent_company
|
gptkb:Samsung_Group
|
|
gptkbp:partnership
|
multiple pharmaceutical companies
|
|
gptkbp:production_volume
|
180,000 liters
|
|
gptkbp:research_focus
|
biopharmaceutical innovation
|
|
gptkbp:revenue
|
over $1 billion (2020)
|
|
gptkbp:services
|
quality control
regulatory support
contract manufacturing
biologics development
|
|
gptkbp:services_provided
|
Contract Manufacturing
Biopharmaceutical Development
|
|
gptkbp:stock_exchange
|
gptkb:KOSDAQ
|
|
gptkbp:sustainability_initiatives
|
energy efficiency measures
waste reduction programs
green manufacturing practices
|
|
gptkbp:bfsParent
|
gptkb:Samsung
|
|
gptkbp:bfsLayer
|
4
|